Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16733331 | 1.00 | ACE (0.33) | ACE | |
| SCHEMBL3660712 | 0.83 | LMNA (0.32) | — | |
| SCHEMBL3392097 | 0.77 | ACE (0.33) | ACE | |
| SCHEMBL17495292 | 0.75 | MAPK1 (0.39) | — | |
| SCHEMBL5420095 | 0.75 | HSD17B10 (0.42) | — | |
| SCHEMBL3274371 | 0.74 | LMNA (0.33) | — | |
| SCHEMBL17510318 | 0.74 | LMNA (0.33) | — | |
| SCHEMBL25364590 | 0.74 | ABAT (0.34) | ACE | |
| SCHEMBL22636529 | 0.74 | ACE (0.32) | ACE | |
| SCHEMBL22636530 | 0.74 | ACE (0.32) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551569-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| WO-2024010794-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11324738-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-05-10 | — | — | US | disclosed |
| EP-3813818-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200129496-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
| US-10548884-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| EP-3331528-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021728-A9 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMTED (GB) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017021728-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMTED (GB) | 2017-02-09 | — | — | WO | disclosed |
| WO-2010062821-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| EP-1891078-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125974-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| EP-1390347-A1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACTIVITY | Applied Research Systems ARS Holding N.V. (AN) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002074741-A1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACITVITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548884-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM4 | ACE 1583/4885 |
| US-20200129496-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM4 | ACE 1693/4885 |
| US-11324738-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM4 | ACE 1693/4885 |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | ACE 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.